Vigil Neuroscience Inc.

1.68
-0.09 (-5.08%)
At close: Apr 03, 2025, 3:59 PM
1.72
2.67%
After-hours: Apr 03, 2025, 05:07 PM EDT

Company Description

Vigil Neuroscience, Inc., a microglia-focused company, engages in the development of disease-modifying therapeutics for patients, caregivers, and families affected by rare and common neurodegenerative diseases.

Its lead product candidate is VGL101, a fully human monoclonal antibody (mAb) that is designed to activate triggering receptor expressed on myeloid cells 2 (TREM2) which is in Phase I for the treatment of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia, as well as for the treatment of cerebral adrenoleukodystrophy and alzheimer's disease.

The company also develops a small molecule TREM2 agonist suitable for oral delivery to treat common neurodegenerative diseases associated with microglial dysfunction.

Vigil Neuroscience, Inc. was incorporated in 2020 and is headquartered in Cambridge, Massachusetts.

Vigil Neuroscience Inc.
Vigil Neuroscience Inc. logo
Country United States
IPO Date Jan 7, 2022
Industry Biotechnology
Sector Healthcare
Employees 69
CEO Dr. Ivana Magovcevic-Liebisch J.D., Ph.D.

Contact Details

Address:
1 Broadway
Cambridge, Massachusetts
United States
Website https://www.vigilneuro.com

Stock Details

Ticker Symbol VIGL
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001827087
CUSIP Number 92673K108
ISIN Number US92673K1088
Employer ID 00-0000000
SIC Code 2836

Key Executives

Name Position
Dr. Ivana Magovcevic-Liebisch J.D., Ph.D. President, Chief Executive Officer & Director
Charles J. Democko Senior Vice President, Regulatory Affairs & Quality
Kevin Durfee Vice President & Head of Information Technology
Ommer Chohan Secretary
Sharon Morani Senior Director of Facilities & Operations

Latest SEC Filings

Date Type Title
Mar 31, 2025 S-3 Filing
Mar 31, 2025 ARS Filing
Mar 31, 2025 DEFA14A Filing
Mar 31, 2025 DEF 14A Filing
Mar 13, 2025 S-8 Filing
Mar 13, 2025 10-K Annual Report
Mar 13, 2025 8-K Current Report
Mar 04, 2025 4 Filing
Mar 04, 2025 4 Filing
Mar 04, 2025 4 Filing